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Ovarian cancer has frequent loss of heterozygosity at
chromosome 12pl2.3-13.1 (region of TEL and Kipi loci)
and chromosome 12q23-ter: evidence for two new
tumour-suppressor genes
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Summary Identification of the key genetic alterations leading to ovarian cancer is in its infancy. Polymerase chain reaction (PCR)-based
analysis of loss of heterozygosity (LOH) is a powerful method for detecting regions of altered tumour-suppressor genes. Focusing on
chromosome 12, we examined 23 ovarian cancer samples for LOH using 31 highly polymorphic microsatellite markers and found the
chromosomal localization of two putative tumour-suppressor genes. Two commonly deleted regions were 12p12.3-13.1 in 6/23 (26%) and
12q23-ter in 7/23 (30%) samples. LOH on chromosome 12 was more common in late-stage ovarian carcinomas. The region of LOH at
12p12.3-13.1 includes the genes that code forthe ETS-family transcriptional factor, known as TEL, and the cyclin-dependent kinase inhibitor,
known as p27('Pl. Mutational analysis of both TEL and p27KiP' using single-strand conformation polymorphism (SSCP) showed no
abnormalities, suggesting that the altered gene in this region is neither of these genes. Taken together, our data suggest that new tumour-
suppressor genes in the region of chromosomes 12p12.3-13.1 and 12q23-ter may be involved in the development of ovarian cancer.
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Ovarian cancer is a frequent cause of cancer death for women.
Recently, scientists have begun to characterize the genetic events
causing ovarian cancer. Amplifications of k-ras (amplified in
4-43% of ovarian cancers; Chien et al, 1990; Borresen, 1992),
c-myc (amplified in 0-29%), c-erbB-2 (HER-21neu; amplified in
0-32%; Slamon et al, 1989; Berchuck et al, 1990; Borresen,
1992),fgfr4 (amplified in two of 11 ovarian tumours; Jaakkola et
al, 1993) were reported, whereas structural alterations ofp16JNK4A
(Hatta et al, 1995a), p15NK4a, pl8JNK4C, pl9INK4D (Park et al, 1997)
and p27KiPI (Kawamata et al, 1995) were rare.
Recent studies demonstrated that inactivation of tumour-
suppressor genes is frequently involved in either the development
or the progression of cancer. Alteration of a tumour-suppressor
gene can be indirectly inferred by analysis of loss of hetero-
zygosity (LOH) using an array of polymorphic genetic markers.
Analysis of LOH has recently become extremely powerful with
the use of polymerase chain reaction (PCR) for highly polymor-
phic microsatellite markers and widely accepted as a means of
identifying the region of tumour-suppressor genes. Knudson's
hypothesis suggests that often one allele of a tumour-suppressor
gene is lost and the second allele is mutated (Knudson, 1971). If
the two alleles were polymorphic, this reduction to homozygosity
could result in LOH.
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In ovarian carcinoma, several chromosome arms have been
reported to be frequently affected by allele loss (Eccles et al, 1990;
Russel etal, 1990; Foulkes etal, 1991; Perez etal, 1991; Sato et al,
1991; Zheng et al, 1991; Saito et al, 1992; Jones and Nakamura,
1992; Viel et al, 1992; Yang-Feng et al, 1992, 1993; Jacobs et al,
1993; Cliby et al, 1993; Foulkes et-al, 1993a,b; Takano et al, 1994;
Koike et al, 1997). At most of the sites of LOH, the tumour-
suppressor genes have not been identified.
Evidence suggests that a gene(s) located on chromosome
12pl2-13 plays an important role in the development ofchildhood
lymphoblastic leukaemia (ALL) and non-small-cell lung cancer
(NSCLC) (Stegmaier et al, 1995; Takeuchi et al, 1996a,b).
Conceming the long arm ofchromosome 12, astudy suggested that
the loss of 12qter occurs in some samples of ovarian cancer using
comparative genomic hybridization (CGH) (Iwabuchi et al, 1995).
In consideration of both sets of data, we performed a detailed
analysis for LOH on chromosome 12, with particular attention to
12pl2-13 and 12qter in ovarian cancers. Although cytogenetic
aberrations ofchromosome 12 have been found in ovarian cancers
(Pejovic et al, 1992), LOH analysis can detect much smaller
regions that harbour an altered tumour-suppressor gene.
We identified two frequently deleted chromosomal regions: one
at 12pl2.3-13.1, which contains two candidates as tumour-
suppressor genes, the ETS-related TEL and the cyclin-dependent
kinase inhibitor (CDKI) known as p27KiPl, and the second at
12q23-ter. As mentioned above, we previously determined that
the p27KiPJ gene was structurally normal in ovarian cancers
(Kawamata et al, 1995). In this study, we determined that the TEL
gene was structurally normal in the ovarian cancer samples with
LOH at 12pl2-13, suggesting that another tumour-suppressor
gene that is altered in ovarian cancer is in the region.
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MATERIALS AND METHODS
Samples
Twenty-three microdissected ovarian cancer samples from
primary tumours were obtained from surgical specimens, along
with either adjacent non-cancerous tissues or peripheral blood
lymphocytes from the same patient as a source of normal DNA.
All the patients were Japanese. The tumours were assigned a histo-
logical subtype and grade according to the Histological Typing of
Ovarian Tumours by the World Health Organization and the
International Federation of Gynecology and Obstetrics (FIGO)
staging system. They included seven clear cell adenocarcinomas
(CCA) (five cases at stage I, one at stage II and one at stage III);
six serous adenocarcinomas (SA) (two cases at stage I, two at
stage III and two at stage IV); three mucinous cystoadenocarci-
nomas (MCA) (one case at stage I, one case at stage II and one at
stage III), three mixed adenocarcinomas (MA) (one case at stage
II, one at stage III and one at stage IV); two mesodermal mixed
tumours (MMT) (one case at stage I and one at stage II) and two
endometrioid adenocarcinomas (EA) (one case at stage III and one
at stage IV). DNA was prepared by proteinase K digestion and
phenol/chloroform extraction.
Microsatellite polymorphisms
Microsatellite markers were analysed using appropriate PCR
primers and DNA amplification. Oligonucleotides were obtained
from Research Genetics (Huntsville, AL, USA). PCRs were
performed as described (Takeuchi et al, 1995b). Briefly, total reac-
tion volumes were 20gl containing 25-75 ng of DNA, 1.5 mm
magnesium chloride, 10 pmol of each of the primers, 2 nmol
of each of the four deoxyribonucleotide triphosphates (dNTP;
Pharmacia, Stockholm, Sweden), 0.5 units of Taq DNA poly-
merase (Gibco-BRL, Gaithersburg, MD, USA), 2,Ci of 32p_
labelled deoxycytidine triphosphate (dCTP) (3000 pCi mmol-1;
New England Nuclear/Dupont, Boston, MA, USA) with specified
buffer provided by the supplier. In order to ascertain LOH ordupli-
cation of the region, PCR reaction was performed in a multiplex
fashion for some of the loci; the reaction mixture included two
primer sets. PCR consisted of40 s at 94°C, 30 s at 55°C and 1 min
at 72°C for 27-32 cycles in a Programmable Thermal Controller
(MJ Research Inc., Water Town, MA, USA). PCR products were
separated on a standard sequencing apparatus (model S2; BRL,
Gaithersburg, MD, USA) with 5-6% polyacrylamide gel, after
which the gels were dried and exposed to Kodak XAR film. Allele
losses were ascertained by visual inspection. When visible reduc-
tion of radiographic signal was not obvious, densitometry was
performed (Ultrascan XL laser densitometer; Pharmacia/LKB,
Freiburg, Germany) to confirm our interpretation.
Table 1 Summary of loss of heterozygosity (LOH) studies in ovarian cancer
12p
Locus LOHWinformative (%)
Dl2S91
Dl 2S100
D112S93
D12S77
Dl2S89
Dl2S98
p27
Dl2S358
D12S320
Dl2S364
D12S269
D12S308
D12S310
D12S363
D12S87
1/8
1/7
2/11
1/8
4/18
0/4
0/1
5/18
4/16
3/19
4/23
3/13
4/23
2/10
2/21
(13)
(14)
(18)
(13)
(22)
(0)
(0)
(28)
(25)
(16)
(17)
(23)
(17)
(20)
(10)
20
T N
12q
Locus LOH/informative (%)
D12S85 0/19 (0)
D12S96 0/7 (0)
D12S90 0/13 (0)
D12S81 3/13 (23)
D12S101 0/4 (0)
D12S346 3/14 (21)
D12S332 3/16 (19)
D12S318 2/11 (18)
Dl2S360 2/9 (22)
Dl 2S78 5/14 (36)
D12S330 2/12 (17)
D12S105 1/10 (10)
D12S84 2/11 (18)
Dl2S354 6/17 (35)
Dl2S369 3/8 (38)
D12S366 1/6 (17)
21
T N
26
T N
D12S90
D12S81 >
D12S366
Analysis of LOH using a polymorphism in exon lb of
the p27KIP1 gene
The p27KiPI gene has been mapped to chromosome 12p (Polyak et
al, 1994; Toyoshima and Hunter, 1994; Ponce-Castaneda et al,
1995; Pieptenol et al, 1995; Bullrich et al, 1995). As wepreviously
reported, exon lb ofthe p27KiPJ gene contains a polymorphism: at
codon 109, guanine is substituted for thymine (GTC to GGC),
resulting in an amino acid substitution ofglycine for valine (Val to
Gly) (Kawamata et al, 1995). By analysing the polymorphism
using polymerase chain reaction-single strand conformation
Figure 1 Autoradiogram demonstrating LOH of tumours (T) compared with
normal (N) tissues in patients with ovarian cancer using microsatellite
markers. Patient numbers are indicated above the panels. Arrowheads show
loss of one allele. The weak signal for the constitutional allele most probably
results from slight contamination of the tumour with normal stromal cells
and/or inflammatory cells
polymorphism (PCR-SSCP), we examined LOH of the p27KiPJ
gene. The PCR-SSCP was performed as described previously
(Kawamata etal, 1995). Primers were synthesizedby Cedars-Sinai
Medical Center Molecular Biology Core.
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ofthem (numbers 3 and 14) showed LOH at all informative loci on
chromosome 12p. This is consistent with loss of one entire chro-
mosome 12p in these two cases. LOH on 12p was more common
in advanced tumours, as an increasing percentage of LOH
occurred in stages II, III and IV compared with stage I, but this
trend was not significant (Table 2).
A second region of LOH on chromosome 12 was the distal
region of 12q. In 7 out of 23 cases (30%), LOH involved the
telomeric portion of 12q from D12S78. Fisher's exact test was
used to compare the frequency ofLOH betweenearly stage (I) and
late stages (II, III and IV) ofovarian cancers. Allele deletion from
12q was found to be significantly associated with advanced
tumours (P < 0.01) (Table 2). Also, four ofthe tumours had LOH
at both 12p and 12q.
The association ofthe serous type ofcarcinoma (SA) with LOH
on chromosome 12 approached but did not reach statistical signif-
icance. In addition, no significant correlation occurred between
any of the histological subtypes and LOH at either 12p or 12q
(Table 3).
Mutational analysis for TEL
For six patients with LOH at 12pl2.3-13.1 (the region ofthe TEL
gene), this gene was examined for alterations using PCR-SSCP.
No aberrant SSCP bands were observed for the matched tumours
and normal tissue for these individuals (Figure 4).
Figure 2 Representative multiplex PCR. The intensity of the D12S78 band
compared with that of D12S100 is demonstrated. Arrowheads show loss of
one allele. T, tumour sample; N, matched normal sample
PCR-SSCP for the TEL gene
The PCR-SSCP analysis for the TEL gene was performed on six
ovarian cancer patients shown to have LOH at the TEL locus. The
eight exons of this gene were amplified via PCR and subjected to
SSCP analysis as previously reported (Stegmaier et al, 1996).
Statistical analysis
The two-tailed Fisher's exact probability test was performed.
P-values < 0.01 were considered statistically significant.
RESULTS
Detection of LOH
Twenty-three pairs of tumour and germline DNAs were tested for
LOH at 15 loci of chromosome 12p and 16 loci of chromosome
12q (Table 1). The mean number ofinformative loci percarcinoma
was 17; the median number was 17; and the range was 13-21 loci.
Representative autoradiograms interpreted as LOH are shown in
Figure 1. The weak signal for the constitutional allele most prob-
ably results from slight contamination of the tumour with normal
stromal cells and/or inflammatory cells. In order to ascertain LOH
or duplication of the region, PCR reaction was performed in a
multiplex fashion for several loci. Increased copy number was not
observed in any ofthe cases having allelic imbalance (Figure 2).
Figure 3 displays the patterns of LOH. Six out of 23 samples
(26%) showed LOH in the 7-cM region defined by D12S89 and
DISCUSSION
In this study, we performed detailed deletional mapping of
chromosome 12 using 31 highly informative markers. All of our
samples were obtained at the time ofinitial surgery for the primary
ovarian cancer; therefore, these results reflect the genetic changes
that are important in the development, rather than in the metastatic
spread, ofthe disease.
We have found LOH on 12p in 26% ofthe samples, and on 12q
in 30% of the samples. Tumour stage is the single best prognostic
predictor in ovarian carcinoma, with 5-year survivals of 80% for
stage I vs 40%, 10% and less than 5% for stages II, III and IV
respectively (DeSouza and Friedlander, 1992). In our study,
increased percentage of LOH on 12p in advanced stages (36%)
compared with stage I (11%) was not significant. However, the
proportion of stage I was relatively high in our collection of
samples. If the stage of the samples had been less biased, overall
frequency ofLOH at chromosome 12 might become higher. Allele
deletion of 12q was significantly associated with advanced
tumours (50% in stages II, III and IV and 0% in stage I; P < 0.01).
Because the background rate of LOH in our samples was 17%
and 18% in stage I and stages II, III and IV, respectively, as has
been previously reported (Takano et al, 1994), the incidence of
LOH on chromosome 12 in advanced tumours was significantly
high and the alteration may be associated with progression of
ovarian cancer.
Allele deletion of chromosome 12 was not associated with
histological subtype ofovarian cancer. However, LOH on chromo-
some 12 was not seen in MCA, which usually has a better prog-
nosis than other types of ovarian cancer. A similar result was
reported by Sato et al (1991). We have demonstrated that LOH
of chromosome 12 is uncommon in CCA, but this result should
be viewed with caution, as five of seven CCA samples are from
British Joumal ofCancer (1997) 75(9), 1256-1262
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Figure 3 Summary of LOH analysis of chomosome 12 in ovarian cancer. Nine samples that showed LOH on chromosome 12 are presented. The status of each
chromosome locus is indicated by shading as LOH (black), retention of heterozygosity (white) and not informative (shaded). Patient numbers are listed at the
top of each column. Asterisks represent the commonly deleted regions
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Table 2 LOH in ovarian cancer on chromosome 12 presented by tumour
stage
Stage 12p LOH(%) 12q LOH (%) 12p and g
LOH (%)
1/9 (11)* 0/9 (0)** 0/9 (0)*
Il, III, IV 5/14 (36)* 7/14 (50)** 4/14 (29)*
*Not significant; "statistically significant (P <0.01); 12p LOH, LOH at
12p12.3-13.1; 12q LOH, LOH at 12q23-ter; 12p and 12q LOH, LOH at both
12p12.3-13.1 and 12q23-ter.
Table 3 LOH in ovarian cancer on chromosome 12 by histological subtype
Histological 12p LOH 12q LOH 12p and q LOH
subtype
CCA 1/7 1/7 0/7
SA 3/6 4/6 2/6
MCA 0/3 0/3 0/3
MA 1/3 1/3 1/3
MMT 1/2 1/2 1/2
EA 0/2 0/2 0/2
CCA, clear cell adenocarcinoma; SA, serous adenocarcinoma; MCA,
mucinous cystoadenocarcinoma; MA, mixed adenocarcinoma; MMT,
mesodermal mixed tumour; EA, endometrioid adenocarcinoma. 12p LOH,
LOH at 12p12.3-13.1; 12q LOH, LOH at 12q23-ter; 12p and q LOH, LOH at
both 12p12.3-13.1 and 12q23-ter.
individuals with stage I ovarian cancer; and therefore, the absence
of LOH might be more of a reflection of their early stage rather
than their histological subtype. Larger studies will be needed to
resolve this issue.
Because both loss and gain ofchromosome 12 in ovarian cancer
have been reported (Pejovic et al, 1992; Iwabuchi et al, 1995), we
performed multiplex PCR for several loci to compare the intensity
of two loci. No amplification of tumours was detected, indicating
that the allelic imbalances were due to LOH.
Two distinct commonly deleted regions were identified in our
ovarian cancer samples. One region is flanked by D12S89 and
D12S364 on 12pl2.3-13.1 and has a size of7 cM, which includes
the previously reported LOH region in NSCLC (Takeuchi et al,
1996b). Therefore, the same uncharacterized tumour-suppressor
gene located in this region is possibly inactivated in ovarian cancer
and NSCLC. Mapping of the critical region of LOH on 12p has
identified two candidate genes: TEL, a newly described ETS-
related gene, and p27kiPl, the gene encoding a CDKI. Ifeither TEL
or p27kiPI are tumour-suppressor genes, the Knudson's two-hit
hypothesis would predict that their mutations would be strongly
associated with LOH ofthe gene (Knudson, 1971).
Recently, TEL was localized between the two microsatellite
markers D12S89 and D12S98 (Stegmaier et al, 1995). TEL was
first reported to be fused with the platelet-derived growth factor
receptor P (PDGFR-,B) in patients with chronic myelomonocytic
leukaemia (CMMoL) having the t(5;12) (q33;pl3) cytogenetic
abnormality (Golub et al, 1994). It was also found to be fused to
ABL, MN] andAML1 in certain types ofhaematological malignan-
cies (Papadopulos et al, 1995; Wlodarska et al, 1995; Buijs et al,
1995; Romana et al, 1995a; Golub et al, 1995). In fact, nearly 20%
of individuals with childhood ALL have a fusion of TEL-AML1
(Shurtleff et al, 1995; Romana et al, 1995b; McLean et al 1996).
Exon 7 Exon 8
I :,-8--8:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.....'.....:.:.:;..:-iG}........i..
':':0'. ' gq
.. -:::.:: ...
Figure 4 PCR-SSCP analysis of TELshowing only exons 7 and 8 as
representative. None of the samples had detectable gel shifts
Paradoxically, the fact that the normal TEL allele is often lost
suggests a unique situation with the TEL-AMLI fusion perhaps
acting as the accelerator of transformation and the normal TEL
product acting as the brake of transformation. In this study of
ovarian cancer, no significant alterations of TEL in any samples
with LOH at l2p12 could be demonstrated as examined by PCR-
SSCPanalysis ofeach ofthe exons. Southern blotanalysis ofthese
samples was not possible because of a paucity ofDNA; therefore,
we cannot conclusively rule out an alteration of the TEL gene in
ovarian cancer.
The p27KiPJ is also a candidate tumour-suppressor gene, in that
othermembers ofthe CDKI family, includingpl5INK4B andpl6INK4A
have been implicated in the pathogenesis of malignancy through
loss offunction (Kamb et al, 1994; Okamoto et al, 1994; Hatta et
al, 1995b; Takeuchi et al, 1995a). Loss offunction ofp27KiPJ might
be expected to accelerate the G1/S transition of the cell cycle
because ofthe unopposed activity ofthe cyclin D/CDK4 orcyclin
E/CDK2 complexes (Poylak et al, 1994; Toyoshima and Hunter,
1994). Mutations of p27KiPI have been reported recently in non-
Hodgkin's lymphoma and adult T-cell leukaemia (Morosetti et al,
1995), but we have previously examined the mutational status of
the p27KiPl gene for ovarian cancers and no detectable deletions
nor point mutations were found (Kawamata et al, 1995). Taken
together, thesefindings suggest that neither the TEL northep27KiPJ
genes behave as tumour-suppressor genes in ovarian cancer, and
another tumour-suppressor gene exists on 12p that is frequently
altered in this disease.
The otherregion ofLOH on chromosome 12 is the distal region
from D12S78 (12q23-ter). This region contains two well-charac-
terized genes, NFYB (Li et al, 1991), a subunit ofNFY, and NOS]
(Xu et al, 1993). NFYis a highly conserved heterometric CCAAT-
binding transcription factor involved in the function of several
promoters, including expression of the major histocompatibility
British Journal ofCancer (1997) 75(9), 1256-1262 t'-w"CancerResearch Campaign 1997LOH of 12p and 12q in ovarian cancer 1261
complex (MHC) class II gene (Montavani et al, 1994; Lloberas
et al, 1995). The absence of expression of MHC class II gene
because of the lack ofNFYB leads to immunodeficiency and may
result in tumorigenesis. NOS] participates in diverse biological
processes, including neurotransmission, homeostasis of body
fluid, neuroendocrine physiology, control of smooth muscle
motility, sexual function and myocyte/myoblast biology (Hall et
al, 1994). Neither NFYB nor NOS] have been reported to be
associated with carcinogenesis and perhaps another, novel gene
contributing to ovarian cancer resides on chromosome 12q23-ter.
Although the number of tumour pairs in our study is not suffi-
cient to reach definitive conclusions, our results suggest that
tumour-suppressor genes at 12pl2.3-13.1 and 12q23-ter may be
altered and play a role in ovarian cancer. The putative tumour-
suppressor gene on 12pl2.3-13.1 is neither TEL nor p27KiPl. By
studying a larger series of ovarian tumours, the regions of LOH
can be further localized leading to the cloning of the tumour-
suppressor genes associated with the development of ovarian
carcinoma.
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